Metal-organic framework NU-1000 integrated cellulose acetate membranes for protein-bound uremic toxin clearance

Technology
In development
University
Scouted & summarized by Halo AI

Novel asymmetric mixed matrix membranes incorporating NU-1000 MOFs into a cellulose acetate matrix for superior clearance of protein-bound uremic toxins. This solution enhances hemodialysis efficiency by combining polymer processability with MOF-based adsorption to improve patient outcomes in end-stage renal disease.

Overview

These asymmetric mixed matrix membranes (MMMs) are engineered to improve the efficacy of hemodialysis by enhancing the removal of protein-bound uremic toxins (PBUTs), which are notoriously difficult to clear with standard dialysis equipment. By integrating a zirconium-based metal-organic framework (MOF), known as NU-1000, into a biodegradable cellulose acetate (CA) matrix, researchers have created an innovative platform that combines the high porosity and structural stability of MOFs with the proven processability of polymer membranes. This approach enables adsorption-assisted transport, allowing the membranes to capture toxins more efficiently than traditional dialysis membranes, directly addressing a critical gap in the treatment of end-stage renal disease (ESRD).

Technical specifications
  • Membrane Composition: Asymmetric structure featuring NU-1000 microcrystals uniformly dispersed within a cellulose acetate polymer matrix.
  • Toxin Removal: Specifically designed to increase the transport and adsorption-assisted clearance of protein-bound toxins, such as indoxyl sulfate.
  • Performance: Crossflow filtration testing has demonstrated a 1.3-fold increase in indoxyl sulfate clearance compared to conventional pristine cellulose acetate membranes.
  • Stability: The NU-1000 framework exhibits high thermal stability (up to 430 degrees Celsius) and maintains structural integrity when incorporated into the polymer.
  • Biocompatibility: Utilizes biodegradable cellulose acetate, promoting an eco-friendly and hemocompatible alternative for clinical applications.
Technology readiness level

The technology is currently at TRL 4. The research has successfully progressed from initial conceptualization and MOF synthesis to laboratory-scale validation. Performance has been demonstrated through crossflow filtration experiments and simulated extracorporeal blood circulation systems, confirming the material's ability to maintain toxin adsorption functionality...

Generated Jul 8, 2026. Please verify key information.

About Universidade de Lisboa

Universidade de Lisboa is a comprehensive public research university in Portugal’s capital, uniting multiple schools and institutes with broad disciplinary coverage. Industry engages through co-located labs, shared core facilities, and campuses linked to research parks and Lisbon’s startup ecosystem. Integration with the university hospital network enables clinical research and translation, while experimental farms and field stations provide real-world testbeds. Research is supported by competitive European and national funding, including the European Commission and Portugal’s Fundação para a Ciência e a Tecnologia (FCT). A dedicated technology transfer office and incubation programs assist with IP, licensing, and startup formation.

Halo home
Partner smarter. Move faster.
Get new partnering requests
delivered to your inbox.